

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### **Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901) [ID6610]**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- |    |  |
|----|--|
| 1. | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|----|--|

It was highlighted during scope consultation that cervical cancer rates are higher in deprived areas and that screening rates are lower in women in deprived areas. The stakeholder who raised this noted that it did not consider that any changes to the draft remit and scope are needed in relation to this issue.
--

- |    |  |
|----|--|
| 2. | What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|----|--|

NICE considers appraisal technologies within their marketing authorisation for the whole population, and for relevant subgroups as defined in section 4.9 of the NICE health technology evaluations manual. As part of the technology appraisal, the committee will also consider the impact of recommendations on people with protected characteristics and the potential impact on health inequalities as outlined in the <a href="#">NICE Principles</a> .
---

- |    |   |
|----|---|
| 3. | Has any change to the draft scope been agreed to highlight potential equality issues? |
|----|---|

No
----

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
None.

**Approved by Principal Technical Adviser (name):** Lizzie Walker

**Date:** 25/09/2025